We are live on
!
Find out more
Entrada Therapeutics
TRDA
TRDA
55 hedge funds and large institutions have $411M invested in Entrada Therapeutics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
36% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 14
6% more capital invested
Capital invested by funds: $390M → $411M (+$21.5M)
0.69% more ownership
Funds ownership: 77.57% → 78.26% (+0.69%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less funds holding
Funds holding: 56 → 55 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Holders
55
Holders Change
-1
Holders Change %
-1.79%
% of All Funds
0.87%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
4
Increased
19
Reduced
14
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$434K |
| 2 |
Millennium Management
New York
|
-$277K |
| 3 |
Man Group
London,
United Kingdom
|
-$219K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$171K |
| 5 |
Morgan Stanley
New York
|
-$141K |
